In imatinib mesylate-sensitive blasts, the association of α-bisabolol and imatinib mesylate led to a synergistic effect which we have conclusively calculated as a CI<1 at any given Fa [16] in the BCR/ABL+ human cell line CML-T1. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.